Skip to content
Screener

Bicara Therapeutics BCAX Q4 2024 Annual earnings

Reported March 27, 2025 · Before market open

EPS-$0.39Miss by $0.08
EPS estimate-$0.31

Next report

Aug 11, 2026 (Tomorrow)
EPS estimate-$0.82

Financials

Q4 2024

Income statement

See full
Operating income-$26.6M-94.6%
Net income-$21.0M-68.5%

Balance sheet

See full
Cash & equivalents$489.7M+113%
Total debt$738.0K+12.3%
Total equity$491.9M+431%
Total assets$510.0M+118%

Cash flow

See full
Operating cash flow-$30.0M-274%
CapEx$40.0K-90.8%
Free cash flow-$30.1M-255%

Valuation & ratios

Valuation

as of 12/31/24
See full
Market cap$947.92M—
Enterprise value$458.95M—

Returns & leverage

See full
Debt / equity0×—
Current ratio27.9×+12.6×

FAQ

When did Bicara Therapeutics report Q4 2024 earnings?
Bicara Therapeutics (BCAX) reported Q4 2024 earnings on March 27, 2025 before market open.
What were Bicara Therapeutics's Q4 2024 revenue and EPS?
Bicara Therapeutics reported eps of $-0.39 for Q4 2024.
Did Bicara Therapeutics beat estimates in Q4 2024?
EPS missed the consensus estimate of $-0.31 by $0.08.
Where can I find Bicara Therapeutics's Q4 2024 SEC filings?
You can read the 8-K earnings release (0002023658-25-000006) and the 10-K periodic report (0002023658-25-000012) directly on SEC EDGAR. The filing index links above go to sec.gov.